EPCAM and neoplasm: As shown in Figure 6, treatment with the CD3xEpCAM bispecific antibody significantly reduced the growth of tumors (Fig. 6A, C) and extended survival of B16F10/EpCAM tumor-bearing mice (Fig. 6B) compared with CD3xnull-treated animals.